Vitamin D Level in Recurrent PV

September 24, 2021 updated by: Rana F Hilal, MD, Kasr El Aini Hospital

Serum Vitamin D Level Detection in Patients With Recurrent Pityriasis Versicolor

Serum Samples will be taken from patients with recurrent Pityriasis Versicolor for the evaluation of vitamin D level.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Anticipated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 58 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients with recurrent Pityriasis Versicolor (more than 2 attacks per year) and of a disseminated nature

Description

Inclusion Criteria:

  • - Patients with recurrent pityriasis versicolor (active now) and not taking treatment for it.
  • Patients of both genders.
  • Age ≥18 years old.

Exclusion Criteria:

  • - Patients with other cutaneous diseases.
  • Patient's having dandruff (scaly scalp) even if not symptomatizing.
  • Pregnant and lactating females, children, prisoners, cognitively impaired or mentally disabled subjects.
  • Patients with autoimmune diseases.
  • Patients with immunodeficiency diseases.
  • Immunosuppressed patients e.g. HIV, diabetics, organ transplant, malignancy, patients taking immunosuppressive drugs e.g. chemotherapy, cortisone.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients
recurrent pityriasis versicolor
Diagnostic test: Human 25-Hydroxyvitamin D3 (HVD3) ELISA Kit (96 well)
The serum will be tested by a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) to assay the level of Human 25Dihydroxy vitamin D（25-OH-D).
Controls
Healthy age and sex matched
Diagnostic test: Human 25-Hydroxyvitamin D3 (HVD3) ELISA Kit (96 well)
The serum will be tested by a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) to assay the level of Human 25Dihydroxy vitamin D（25-OH-D).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Serum 25(OH) D3 level
Time Frame: 6months-1 year
The serum of patients and controls will be tested by a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) to assay the level of Human 25Dihydroxy vitamin D（25-OH-D).
6months-1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Kasr El Aini Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2021

Primary Completion (Anticipated)

January 1, 2022

Study Completion (Anticipated)

March 1, 2022

Study Registration Dates

First Submitted

September 24, 2021

First Submitted That Met QC Criteria

September 24, 2021

First Posted (Actual)

October 5, 2021

Study Record Updates

Last Update Posted (Actual)

October 5, 2021

Last Update Submitted That Met QC Criteria

September 24, 2021

Last Verified

September 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • VitD&PV

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Recurrent Pityriasis Versicolor

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe